Che Jizhong, Liu Yuanyuan, Liu Yangyang, Song Jingheng, Cui Hongguo, Feng Dongdong, Tian Aimin, Zhang Zhengchao, Xu Yankai
Department of Urology, Yantai Affiliated Hospital of Binzhou Medical University, The Second Clinical Medical College of Binzhou Medical University, Yantai, Shandong, China.
Department of Urology, Haiyang City People's Hospital, Yantai, Shandong, China.
Front Immunol. 2025 Mar 12;16:1544882. doi: 10.3389/fimmu.2025.1544882. eCollection 2025.
In recent years, there has been a growing trend towards the utilization of immunotherapy techniques for the treatment of cancer. Some malignancies have acquired significant progress with the use of cancer vaccines, immune checkpoint inhibitors, and adoptive cells therapy. Scholars are exploring the aforementioned methods as potential treatments for advanced prostate cancer (PCa) due to the absence of effective adjuvant therapy to improve the prognosis of metastatic castration-resistant prostate cancer (mCRPC). Immunotherapy strategies have yet to achieve significant advancements in the treatment of PCa, largely attributed to the inhibitory tumor microenvironment and low mutation load characteristic of this malignancy. Hence, researchers endeavor to address these challenges by optimizing the design and efficacy of immunotherapy approaches, as well as integrating them with other therapeutic modalities. To date, studies have also shown potential clinical benefits. This comprehensive review analyzed the utilization of immunotherapy techniques in the treatment of PCa, assessing their advantages and obstacles, with the aim of providing healthcare professionals and scholars with a comprehensive understanding of the progress in this field.
近年来，利用免疫治疗技术治疗癌症的趋势日益增长。使用癌症疫苗、免疫检查点抑制剂和过继性细胞疗法治疗某些恶性肿瘤已取得显著进展。由于缺乏有效的辅助治疗来改善转移性去势抵抗性前列腺癌（mCRPC）的预后，学者们正在探索上述方法作为晚期前列腺癌（PCa）的潜在治疗方法。免疫治疗策略在PCa治疗中尚未取得重大进展，这在很大程度上归因于这种恶性肿瘤的抑制性肿瘤微环境和低突变负荷特征。因此，研究人员努力通过优化免疫治疗方法的设计和疗效，并将其与其他治疗方式相结合来应对这些挑战。迄今为止，研究也显示出了潜在的临床益处。这篇综述分析了免疫治疗技术在PCa治疗中的应用，评估了它们的优势和障碍，旨在让医疗专业人员和学者全面了解该领域的进展。
